Probiotic supplementation: A prospective approach in the treatment of COVID-19

Atiyeh Nayebi1,2, Jamshid Gholizadeh Navashenaq3, Davood Soleimani1,4

  • 1Student Research Committee, Nutritional Sciences Department, School of Nutrition Sciences and Food Technology, 48464Kermanshah University of Medical Sciences, Kermanshah, Iran.

Nutrition and Health
|November 8, 2021
PubMed

Insights

Probiotics may help reduce COVID-19 severity by directly fighting SARS-CoV and suppressing harmful immune responses. This gut health intervention shows promise as an adjuvant therapy for coronavirus disease 2019.

Area of Science:

  • Microbiology
  • Immunology
  • Virology

Background:

  • Coronavirus disease 2019 (COVID-19) poses a global health challenge, impacting respiratory and gastrointestinal systems.
  • Severe cases involve impaired immune responses, cytokine storms, acute lung injury, and thrombus formation.
  • Probiotics, beneficial microorganisms, are known to support host health.

Purpose of the Study:

  • To investigate the role of gut dysbiosis in viral infections, particularly COVID-19.
  • To evaluate the impact of probiotic consumption on preventing severe COVID-19 symptoms.

Main Methods:

  • Comprehensive literature search of SCOPUS, PubMed, and Google Scholar databases.
  • Focused on studies examining the relationship between probiotics and viral infections, extending to COVID-19.
  • Synthesized evidence on probiotic effects on viral countermeasures and immune modulation.

Main Results:

  • Probiotics demonstrate direct antiviral activity against SARS-CoV in both gastrointestinal and respiratory tracts.
  • Probiotics effectively suppress excessive immune responses and prevent cytokine storms.
  • Probiotic use modulates immune responses, mitigating pathological inflammation.

Conclusions:

  • Probiotics exhibit antiviral and respiratory protective activities.
  • Consumption of probiotics may serve as an effective adjuvant therapy for COVID-19.
  • Probiotics show potential in reducing the overall burden and severity of COVID-19.

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
483
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
354
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
451
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
622
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
384
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
236